MIMEDX GROUP, INC.MDXG

MIMEDX GROUP, INC. Revenue Disclosure

10-KFiled Feb 25, 20262 min read
Revenue
Net Sales By Product Category
MIMEDX has two product categories: (1) Wound, which reflects products typically used in Advanced Wound Care settings, including the treatment of chronic, non-healing wounds, and (2) Surgical, which reflects products principally used in surgical settings, including the closure of acute wounds or to protect and reinforce tissues and/or regions of interest. The Company manages its product portfolio and pipeline based upon opportunities in each of these settings.
Below is a summary of net sales by product line (in thousands):
Year Ended December 31,
2025
2024
2023
Wound
$
276,326 
$
231,004 
$
205,660 
Surgical
142,304 
117,875 
115,817 
Total
$
418,630 
$
348,879 
$
321,477 
The Company did not have significant foreign operations or a single external customer from which 10% or more of net sales were derived during the years ended December 31, 2025, 2024, or 2023.
Reimbursement Changes
In response to market dynamics that have resulted in increasing Medicare spend on skin substitutes in the physician office and associated care settings over the past several years, Medicare implemented changes related to the reimbursement of skin substitutes, effective with the implementation of the 2026 Physician Fee Schedule and 2026 Hospital Outpatient Prospective Payment System on January 1, 2026. These changes include: 1) reimbursing skin substitute products uniformly across the hospital outpatient department and physician office and associated care settings and 2) capping the reimbursement rate for skin substitutes at $127.14 per square centimeter in these care settings, subject to geographic adjustments.
These adjustments could adversely affect revenue derived from the Company’s Wound category beginning in 2026.
Sales Returns Allowance
Activity related to the Company’s sales returns allowance during the year ended December 31, 2025 was as follows (in thousands):
Sales Returns Allowance
Balance at December 31, 2023
$1,096 
Additions4,314 
Deductions and write-offs(3,420)
Balance at December 31, 2024
1,990 
Additions8,357 
Deductions and write-offs(7,912)
Balance at December 31, 2025
$2,435 

Historical Timeline

Fiscal YearFiled
2025Feb 25, 2026Showing above
2024Feb 26, 2025
2023Feb 28, 2024
2022Feb 28, 2023
2021Feb 28, 2022
2020Mar 8, 2021
2019Jul 6, 2020
2018Mar 17, 2020
2016Mar 1, 2017

About Revenue Disclosures

Revenue disclosures under ASC 606 explain how a company identifies performance obligations, allocates transaction prices, and determines when revenue is recognized. This section is essential for understanding whether reported revenue reflects genuine economic activity or aggressive accounting choices. Analysts examine the mix of point-in-time versus over-time recognition, which directly affects revenue timing and comparability.

Key signals: rising contract liabilities (deferred revenue) suggest strong future revenue visibility, while declining contract assets may indicate slowing project milestones. Watch for variable consideration estimates — rebates, returns, and performance bonuses that require management judgment. Significant changes in disaggregated revenue by geography or product line can reveal shifting business mix before it appears in headline numbers. Compare revenue growth against contract liability growth to assess sustainability, and scrutinize any changes in the timing of recognition that coincide with earnings pressure.

Other Available Disclosures

Income TaxesEarnings Per SharePP&EGoodwill & IntangiblesLeasesSegmentsDebtCommitmentsStock CompensationNew StandardsPay vs Performance